Investor Presentation regarding Bliss GVS Pharma Limited Acquisition.
ANURAS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Anupam Rasayan India Ltd is acquiring a controlling stake (43.3-48.2%+) in Bliss GVS Pharma Limited, an India-based pharmaceutical formulations company. The deal will be funded via a term loan of ~Rs 300 Crores and a non-controlling non-voting equity instrument. Bliss GVS Pharma has revenues of Rs 927 Cr (FY26 projected) with zero net debt and Rs 139 Cr cash flow from operations. The target company has 6 manufacturing facilities, 150+ brands across 50+ therapeutic segments, and holds US FDA, EU GMP, and other global accreditations. Key synergies include expansion into regulated markets, capacity utilization ramp-up (currently only 30%), and forward integration into multiple therapeutic areas including Cardiovascular, Anti-diabetic, and Antibiotics.
This acquisition will expand Anupam's product portfolio and manufacturing capabilities, with significant margin improvement potential as EBITDA margins are projected to rise from 11% to 20% and capacity utilization increases from current low levels.